Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $82.16M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.03M
Average 0.25M
RLYB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Rallybio CorporationNASDAQ: RLYB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $68K fell 98.8% year over year, behind the -59.3% change in trailing-twelve-month research & development. Sequentially, it fell 98.1% from the prior quarter. Over 3 fiscal years it compounded at -21.6% a year.
Context
- Research & development amounted to 2284.0% of revenue in FY2025, down 4242.2 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -98.8% toward the trailing-twelve-month pace of -59.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.6M USD
- Year-over-year change
- -52.8%
- 4-year CAGR
- -7.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.6M | -52.8% |
| FY2024 | 2024-12-31 | 41.51M | -22.5% |
| FY2023 | 2023-12-31 | 53.54M | +31.6% |
| FY2022 | 2022-12-31 | 40.69M | +51.2% |
| FY2021 | 2021-12-31 | 26.91M | — |
Research & Development vs competitors
How RLYB compares with its peers on the latest reported figures
- RLYB's LTM Mar 2026 research & development of $13.94M is the lowest of the 4 companies compared; the peer median is $19.64M.
- Its year-over-year change of -59.3% is the 3rd highest of 4, against a peer median of -21.4%.
- Research & development amounts to 1624.7% of revenue for RLYB, versus a peer median of 9835.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $42.44M | -21.4% | +6.5% | — | |
| LTM Jun 2026 | $19.64M | +136.3% | +23.9% | 19643.0% | |
| LTM Mar 2026 | $15.25M | -66.4% | -18.8% | 28.4% | |
| LTM Mar 2026 | $13.94M | -59.3% | -21.6% | 1624.7% | |
| Peer median (excluding RLYB) | $19.64M | -21.4% | +6.5% | 9835.7% | |
Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 636K | 858K |
| Cost of Revenue | 109K | 167K | 150K | 131K | 92K |
| Gross Profit | (109K) | (167K) | (150K) | 636K | 766K |
| Gross Margin | — | — | — | 100.0% | 89.3% |
| Research & Development | 26.91M | 40.69M | 53.54M | 41.51M | 19.6M |
| Selling, General & Admin | 18.74M | 27.2M | 25.39M | 19.63M | 14.33M |
| Operating Expenses | 45.65M | 67.88M | 78.93M | 61.13M | 28.83M |
| Depreciation & Amortization | 109K | 167K | 150K | 131K | 92K |
| EBITDA | (45.39M) | (67.72M) | (78.78M) | (60.37M) | (27.97M) |
| EBITDA Margin | — | — | — | -9491.4% | -3260.1% |
| Operating Income | (45.65M) | (67.88M) | (78.93M) | (60.5M) | (28.06M) |
| Operating Margin | — | — | — | -9511.9% | -3270.9% |
| Interest Income | 54K | 1.96M | 6.15M | 4.22M | 2.19M |
| Interest Expense | 10K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.37M) | 1.23M | 4.37M | 2.72M | 19.09M |
| Income Before Tax | (47.01M) | (67.73M) | (74.56M) | (57.78M) | (8.98M) |
| Pre-Tax Margin | — | — | — | -9084.1% | -1046.4% |
| Income Tax Expense | 0 | (1.08M) | 0 | 0 | 0 |
| Net Income | (47.01M) | (66.65M) | (74.56M) | (57.78M) | (8.98M) |
| Net Margin | — | — | — | -9084.1% | -1046.4% |
| EPS (Basic) | (11.68) | (16.72) | (14.72) | (10.64) | (1.59) |
| EPS (Diluted) | (11.68) | (16.72) | (14.72) | (10.64) | (1.59) |
| Weighted Avg Shares | 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
| Weighted Avg Shares (Diluted) | 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
Rallybio Corporation
NASDAQ:RLYB
Intrinsic Alpha fair value
Locked
Current Price
$15.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.